# EDGAR Filing Document

**Accession Number:** 0001889109
**File Stem:** 0001193125-26-173761
**Filing Date:** 2026-4
**Character Count:** 9582
**Document Hash:** 6ebf4bf6cae8495cf76273a1db8cbfc7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-173761.hdr.sgml**: 20260423

**ACCESSION NUMBER**: 0001193125-26-173761

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260422

**FILED AS OF DATE**: 20260423

**DATE AS OF CHANGE**: 20260423

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** MATA NATHAN L.
- **CENTRAL INDEX KEY:** 0002013987

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41359
- **FILM NUMBER:** 26888922

**MAIL ADDRESS:**
- **STREET 1:** 7708 MARKER ROAD
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BELITE BIO, INC
- **CENTRAL INDEX KEY:** 0001889109
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 12750 HIGH BLUFF DRIVE SUITE 475
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 858-246-6240

**MAIL ADDRESS:**
- **STREET 1:** 12750 HIGH BLUFF DRIVE SUITE 475
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>MATA NATHAN L.<br><sub>(Last) (First) (Middle)</sub><br>7708 MARKER ROAD<br><sub>(Street)</sub><br>SAN DIEGO, CA 92130<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-22 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Scientific Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>BELITE BIO, INC [ BLTE ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| American depositary share<sup>(1)</sup> | 2026-04-22 |  | S<sup>(2)</sup> |  | 31 | D | 165.7010<sup>(3)</sup> | 11635 | D |  |
| American depositary share<sup>(1)</sup> | 2026-04-22 |  | S<sup>(2)</sup> |  | 20 | D | 166.3200<sup>(4)</sup> | 11615 | D |  |
| American depositary share<sup>(1)</sup> | 2026-04-22 |  | S<sup>(2)</sup> |  | 141 | D | 167.4206<sup>(5)</sup> | 11474 | D |  |
| American depositary share<sup>(1)</sup> | 2026-04-22 |  | S<sup>(2)</sup> |  | 101 | D | 168.6355<sup>(6)</sup> | 11373 | D |  |
| American depositary share<sup>(1)</sup> | 2026-04-22 |  | S<sup>(2)</sup> |  | 105 | D | 169.5236<sup>(7)</sup> | 11268 | D |  |
| American depositary share<sup>(1)</sup> | 2026-04-22 |  | S<sup>(2)</sup> |  | 75 | D | 170.5833<sup>(8)</sup> | 11193 | D |  |
| American depositary share<sup>(1)</sup> | 2026-04-22 |  | S<sup>(2)</sup> |  | 257 | D | 171.6150<sup>(9)</sup> | 10936 | D |  |
| American depositary share<sup>(1)</sup> | 2026-04-22 |  | S<sup>(2)</sup> |  | 249 | D | 172.4901<sup>(10)</sup> | 10687 | D |  |
| American depositary share<sup>(1)</sup> | 2026-04-22 |  | S<sup>(2)</sup> |  | 21 | D | 173.041<sup>(11)</sup> | 10666 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.

(2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.

(3) Represents the weighted average price of shares sold at prices that ranged from $165.64 to $165.71. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

(4) Represents the weighted average price of shares sold at prices that ranged from $166.19 to $166.71. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

(5) Represents the weighted average price of shares sold at prices that ranged from $167.08 to $167.86. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

(6) Represents the weighted average price of shares sold at prices that ranged from $168 to $168.9. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

(7) Represents the weighted average price of shares sold at prices that ranged from $169.08 to $169.78. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

(8) Represents the weighted average price of shares sold at prices that ranged from $170 to $170.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

(9) Represents the weighted average price of shares sold at prices that ranged from $171.01 to $171.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

(10) Represents the weighted average price of shares sold at prices that ranged from $172 to $172.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

(11) Represents the weighted average price of shares sold at prices that ranged from $173 to $173.16. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

**Signature:** /s/ Nathan L. Mata  
**Date:** 2026-04-23

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**